Concise synthesis of JN403, a novel nicotinic acetylcholine receptor 7 selective agonist

Synthetic Communications

Volumn 39, Issue 15, 2009, Pages 2640-2646

  Jiang, Xinglong ^a   Prasad, Kapa ^a   Repic, Oljan ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Condensation; Hydrochloride salt; N Butyllithium; Neutralization

Indexed keywords

(1 AZABICYCLO[2.2.2]OCT 3 YL)CARBAMIC ACID 1 (2 FLUOROPHENYL)ETHYL ESTER; BUNGAROTOXIN RECEPTOR; BUTYLLITHIUM; JN 403; LITHIUM DERIVATIVE; NICOTINIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; POLYMERIZATION; REACTION ANALYSIS;

EID: 67650318000     PISSN: 00397911     EISSN: 15322432     Source Type: Journal    
DOI: 10.1080/00397910802663378     Document Type: Article

References (3)

1. Feuerbach, D.; Nozulak, J.; Lingenhoehl, K.; McAllister, K.; Hoyer, D. JN403, in vitro characterization of a novel nicotinic acetylcholine receptor a-7 selective agonist. Neurosci. Lett. 2007, 416, 61-65.
2. Nozulak, J. Preparation of azabicyclic carbamate derivatives and their use as alpha-7-nicotinic acetylcholine receptor agonists. PCT Int. Appl. WO 2001085727, CAN 135:358082, AN 2001:833315, 2001.
3. Garrett, C. E.; Prasad, K.; Repič, O.; Blacklock, T. J. The enantioselective reduction of 20-fluoroacetophenone utilizing a simplified CBS-reduction procedure. Tetrahedron: Asymmetry 2002, 13, 1347-1349.